Ulotaront, an investigational trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, flopped in two phase III studies for schizophrenia, though developers Sumitomo Pharma and Otsuka blamed this in part on the COVID-19 pandemic boosting the placebo effect.
Trauma-focused, internet-delivered cognitive therapy was superior to a non-trauma-focused cognitive behavioral stress management therapy for reducing post-traumatic stress disorder (PTSD) symptoms in a 13-week trial. (The Lancet Psychiatry)
McLean Hospital in Belmont, Massachusetts nabbed the top spot on the U.S. News & World Report‘s list of top hospitals for psychiatry in 2023-2024. The second and third spots went to Massachusetts General Hospital in Boston and New York-Presbyterian Hospital-Columbia and Cornell in New York City.
The FDA approved a second over-the-counter naloxone hydrochloride nasal spray (RiVive) for reversing opioid overdoses.
The Flow tDCS headset, a non-invasive brain stimulation device under review by the FDA, showed twice the efficacy of the most commonly prescribed antidepressants for depression in a 10-week trial, maker Flow Neuroscience announced.
Based on data from global surveys among over 156,000 people from 29 countries, about half the population can expect to develop one or more of 13 DSM-IV-defined mental disorders by age 75. (The Lancet Psychiatry)
People addicted to cannabis are often met with skepticism. (Washington Post)
A BMC Psychiatry case study detailed a 19-year-old patient with type 1 diabetes and Cotard’s syndrome — a condition in which patients believe they’re already dead — who was admitted to the hospital for diabetic ketoacidosis after saying “a ghost doesn’t need insulin.”
![author['full_name']](https://clf1.medpagetoday.com/media/images/author/kristenMonaco_188.jpg)
Please enable JavaScript to view the